Patient, disease, and transplant characteristics according to treatment arm
| Characteristic . | Inolimomab (n = 49) . | ATG (n = 51) . | P . |
|---|---|---|---|
| Sex, n (%) | .555 | ||
| Male | 22 (44.9) | 26 (51) | |
| Female | 27 (55.1) | 25 (49) | |
| Age, mean (SD) | 46.2 (12.6) | 47.1 (12.96) | .727 |
| Disease | |||
| AML/MDS/MPD | 14/4/2 | 10 / 7 / 2 | |
| ALL | 7 | 6 | NS |
| CLL/lymphoma/myeloma | 4 / 8 / 4 | 6 / 10 / 7 | |
| Other | 8 | 3 | |
| CR at HSCT, n (%) | 26 (53.1) | 28 (54.9) | .905 |
| Source of cells, n (%) | |||
| Peripheral blood | 40 (81.6) | 39 (76.5) | .698 |
| Marrow | 9 (18.4) | 12 (23.5) | |
| GVHD prophylaxis, n (%) | |||
| CSA + MTX | 23 (46.9) | 21 (41.2) | .704 |
| CSA + MMF | 22 (44.8) | 19 (37.3) | .566 |
| ATG | 13 (26.5) | 11 (21.5) | .72 |
| Donor type, n (%) | |||
| Matched sibling | 15 (30.6) | 20 (39.2) | .489 |
| Matched UD (10/10 allelic) | 31 (63.3) | 30 (58.8) | .802 |
| 9/10 UD | 3 (6.1) | 1 (2) | .581 |
| Donor characteristic | |||
| Age, mean (SD) | 39.3 (12.5) | 37.0 (12.3) | .821 |
| Sex (M/F) | 31/18 | 37/14 | .435 |
| Conditioning regimen, n (%) | |||
| Myeloablative | 21 (42.9) | 19 (37.3) | .713 |
| Reduced intensity | 28 (57.1) | 32 (62.7) | .713 |
| Irradiation-based | 18 (36.7) | 14 (27.4) | .435 |
| Characteristic . | Inolimomab (n = 49) . | ATG (n = 51) . | P . |
|---|---|---|---|
| Sex, n (%) | .555 | ||
| Male | 22 (44.9) | 26 (51) | |
| Female | 27 (55.1) | 25 (49) | |
| Age, mean (SD) | 46.2 (12.6) | 47.1 (12.96) | .727 |
| Disease | |||
| AML/MDS/MPD | 14/4/2 | 10 / 7 / 2 | |
| ALL | 7 | 6 | NS |
| CLL/lymphoma/myeloma | 4 / 8 / 4 | 6 / 10 / 7 | |
| Other | 8 | 3 | |
| CR at HSCT, n (%) | 26 (53.1) | 28 (54.9) | .905 |
| Source of cells, n (%) | |||
| Peripheral blood | 40 (81.6) | 39 (76.5) | .698 |
| Marrow | 9 (18.4) | 12 (23.5) | |
| GVHD prophylaxis, n (%) | |||
| CSA + MTX | 23 (46.9) | 21 (41.2) | .704 |
| CSA + MMF | 22 (44.8) | 19 (37.3) | .566 |
| ATG | 13 (26.5) | 11 (21.5) | .72 |
| Donor type, n (%) | |||
| Matched sibling | 15 (30.6) | 20 (39.2) | .489 |
| Matched UD (10/10 allelic) | 31 (63.3) | 30 (58.8) | .802 |
| 9/10 UD | 3 (6.1) | 1 (2) | .581 |
| Donor characteristic | |||
| Age, mean (SD) | 39.3 (12.5) | 37.0 (12.3) | .821 |
| Sex (M/F) | 31/18 | 37/14 | .435 |
| Conditioning regimen, n (%) | |||
| Myeloablative | 21 (42.9) | 19 (37.3) | .713 |
| Reduced intensity | 28 (57.1) | 32 (62.7) | .713 |
| Irradiation-based | 18 (36.7) | 14 (27.4) | .435 |
ALL, acute lymphoblastic leukemia; AML, acute myelogenous leukemia; CLL, chronic lymphocytic leukemia; CSA, cyclosporine; MDS, myelodysplastic syndrome; MPD, myeloproliferative disorders; MTX, methotrexate; SD, standard deviation; UD; unrelated donor.